Sestrin2 protects dopaminergic cells against rotenone toxicity through AMPK-dependent autophagy activation

Molecular and Cellular Biology

Volumn 35, Issue 16, 2015, Pages 2740-2751

  Hou, Yi Sheng ^a   Guan, Jun Jie ^a   Xu, Hai Dong ^a   Wu, Feng ^a   Sheng, Rui ^a   Qin, Zheng Hong ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CASPASE 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; PROTEIN; ROTENONE; SESTRIN2 PROTEIN; UNCLASSIFIED DRUG; NUCLEAR PROTEIN; SESTRIN 2 PROTEIN, RAT; UNCOUPLING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; IN VITRO STUDY; NEUROBLASTOMA CELL; NONHUMAN; PC12 CELL LINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; CELL LINE; DRUG EFFECTS; GENETICS; METABOLISM; PARKINSON DISEASE; PATHOLOGY; TRANSCRIPTION INITIATION;

ALPHA-SYNUCLEIN; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; AUTOPHAGY; CASPASE 3; CELL LINE; DOPAMINERGIC NEURONS; NUCLEAR PROTEINS; PARKINSON DISEASE, SECONDARY; RATS; ROTENONE; TRANSCRIPTIONAL ACTIVATION; UNCOUPLING AGENTS; UP-REGULATION;

EID: 84937935513     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00285-15     Document Type: Article

References (70)

1. Dauer W, Przedborski S. 2003. Parkinson's disease: mechanisms and models. Neuron 39:889-909. http://dx.doi.org/10.1016/S0896-6273(03) 00568-3
2. Kahle PJ, Haass C, Kretzschmar HA, Neumann M. 2002. Structure/ function of alpha-synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. J Neurochem 82:449-457. http://dx.doi.org/10.1046/j.1471-4159.2002.01020.x
3. Decressac M, Mattsson B, Lundblad M, Weikop P, Bjorklund A. 2012. Progressive neurodegenerative and behavioural changes induced by AAVmediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol Dis 45:939-953. http://dx.doi.org/10.1016/j.nbd.2011.12.013
4. Xilouri M, Vogiatzi T, Vekrellis K, Park D, Stefanis L. 2009. Aberrant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS One 4:e5515. http://dx.doi.org/10.1371/journal.pone.0005515
5. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL. 1999. Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 274:19509-19512.
6. Luk KC, Song C, O'Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, LeeVM.2009. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad SciUSA106:20051-20056. http://dx.doi.org/10.1073/pnas.0908005106.
7. Shacka JJ, Roth KA, Zhang J. 2008. The autophagy-lysosomal degradation pathway: role in neurodegenerative disease and therapy. Front Biosci 13:718-736. http://dx.doi.org/10.2741/2714
8. Nixon RA. 2013. The role of autophagy in neurodegenerative disease. Nat Med 19:983-997. http://dx.doi.org/10.1038/nm.3232
9. Dehay B, Martinez-Vicente M, Caldwell GA, Caldwell KA, Yue Z, Cookson MR, Klein C, Vila M, Bezard E. 2013. Lysosomal impairment in Parkinson's disease. Mov Dis 28:725-732. http://dx.doi.org/10.1002 /mds.25462
10. Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, Adame A, Wyss-Coray T, Masliah E. 2009. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha- synuclein models of Parkinson's and Lewy body diseases. J Neurosci 29:13578-13588. http://dx.doi.org/10.1523/JNEUROSCI.4390-09.2009
11. Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, Tanaka K. 2006. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441:880-884. http://dx.doi.org/10.1038/nature04723
12. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. 2004. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305:1292-1295. http://dx.doi.org/10.1126/science.1101738
13. Massey AC, Kaushik S, Sovak G, Kiffin R, Cuervo AM. 2006. Consequences of the selective blockage of chaperone-mediated autophagy. Proc Natl Acad Sci U S A 103:5805-5810. http://dx.doi.org/10.1073/pnas.0507436103
14. Li L, Zhang X, Le W. 2008. Altered macroautophagy in the spinal cord of SOD1 mutant mice. Autophagy 4:290-293. http://dx.doi.org/10.4161/auto .5524
15. Morimoto N, Nagai M, Ohta Y, Miyazaki K, Kurata T, Morimoto M, Murakami T, Takehisa Y, Ikeda Y, Kamiya T, Abe K. 2007. Increased autophagy in transgenic mice with a G93A mutant SOD1 gene. Brain Res 1167:112-117. http://dx.doi.org/10.1016/j.brainres.2007.06.045
16. Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Bjorklund A. 2013. TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity. Proc Natl Acad Sci U S A 110:E1817-E1826. http://dx.doi.org/10.1073/pnas.1305623110
17. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton DF, Duden R, O'Kane CJ, Rubinsztein DC. 2004. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36:585-595. http://dx.doi.org/10.1038/ng1362
18. Lafay-Chebassier C, Paccalin M, Page G, Barc-Pain S, Perault-Pochat MC, Gil R, Pradier L, Hugon J. 2005. mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease. J Neurochem 94:215-225. http://dx.doi.org/10.1111/j.1471-4159.2005.03187.x
19. Malagelada C, Ryu EJ, Biswas SC, Jackson-Lewis V, Greene LA. 2006. RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation. J Neurosci 26:9996-10005. http://dx.doi.org/10.1523/JNEUROSCI.3292-06.2006
20. Santini E, Heiman M, Greengard P, Valjent E, Fisone G. 2009. Inhibition ofmTORsignaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. Sci Signal 2:ra36.
21. Tain LS, Mortiboys H, Tao RN, Ziviani E, Bandmann O, Whitworth AJ. 2009. Rapamycin activation of 4E-BP prevents Parkinsonian dopaminergic neuron loss. Nat Neurosci 12:1129-1135. http://dx.doi.org/10.1038 /nn.2372
22. Kim J, Kundu M, Viollet B, Guan KL. 2011. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13:132-141. http://dx.doi.org/10.1038/ncb2152
23. Russell RC, Tian Y, Yuan H, Park HW, Chang YY, Kim J, Kim H, Neufeld TP, Dillin A, Guan KL. 2013. ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase. Nat Cell Biol 15:741-750. http://dx.doi.org/10.1038/ncb2757
24. Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, Vasquez DS, Joshi A, Gwinn DM, Taylor R, Asara JM, Fitzpatrick J, Dillin A, Viollet B, Kundu M, Hansen M, Shaw RJ. 2011. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331:456-461. http://dx.doi.org/10 .1126/science.1196371
25. Egan D, Kim J, Shaw RJ, Guan KL. 2011. The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR. Autophagy 7:643-644. http://dx.doi.org/10.4161/auto.7.6.15123
26. Pan T, Rawal P, Wu Y, Xie W, Jankovic J, Le W. 2009. Rapamycin protects against rotenone-induced apoptosis throughautophagyinduction. Neuroscience 164:541-551. http://dx.doi.org/10.1016/j.neuroscience.2009.08.014
27. Budanov AV, Karin M. 2008. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134:451-460. http://dx.doi.org/10.1016/j.cell.2008.06.028
28. Lee JH, Budanov AV, Talukdar S, Park EJ, Park HL, Park HW, Bandyopadhyay G, Li N, Aghajan M, Jang I, Wolfe AM, Perkins GA, Ellisman MH, Bier E, Scadeng M, Foretz M, Viollet B, Olefsky J, Karin M. 2012. Maintenance of metabolic homeostasis by Sestrin2 and Sestrin3. Cell Metab 16:311-321. http://dx.doi.org/10.1016/j.cmet.2012.08.004
29. Bae SH, Sung SH, Oh SY, Lim JM, Lee SK, Park YN, Lee HE, Kang D, Rhee SG. 2013. Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage. Cell Metab 17:73-84. http://dx.doi.org/10.1016/j.cmet.2012.12.002
30. Soloway SB. 1976. Naturally occurring insecticides. Environ Health Perspect 14:109-117. http://dx.doi.org/10.1289/ehp.7614109
31. Sherer TB, Kim JH, Betarbet R, Greenamyre JT. 2003. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 179:9-16. http://dx.doi.org/10 .1006/exnr.2002.8072
32. Aguilar V, Alliouachene S, Sotiropoulos A, Sobering A, Athea Y, Djouadi F, Miraux S, Thiaudiere E, Foretz M, Viollet B, Diolez P, Bastin J, Benit P, Rustin P, Carling D, Sandri M, Ventura-Clapier R, Pende M. 2007. S6 kinase deletion suppresses muscle growth adaptations to nutrient availability by activating AMP kinase. Cell Metab 5:476-487. http://dx .doi.org/10.1016/j.cmet.2007.05.006
33. Budanov AV, Lee JH, Karin M. 2010. Stressin' Sestrins take an aging fight. EMBO Mol Med 2:388-400. http://dx.doi.org/10.1002/emmm.201000097
34. Maiuri MC, Malik SA, Morselli E, Kepp O, Criollo A, Mouchel PL, Carnuccio R, Kroemer G. 2009. Stimulation of autophagy by the p53 target gene Sestrin2. Cell Cycle 8:1571-1576. http://dx.doi.org/10.4161/cc.8.10.8498
35. Choi JS, Park C, Jeong JW. 2010. AMP-activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem Biophys ResCommun391:147-151. http://dx.doi.org/10.1016/j.bbrc.2009.11.022.
36. Spasic MR, Callaerts P, Norga KK. 2009. AMP-activated protein kinase (AMPK) molecular crossroad for metabolic control and survival of neurons. Neuroscientist 15:309-316. http://dx.doi.org/10.1177/1073858408327805
37. Klucken J, Poehler AM, Ebrahimi-Fakhari D, Schneider J, Nuber S, Rockenstein E, Schlotzer-Schrehardt U, Hyman BT, McLean PJ, Masliah E, Winkler J. 2012. Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. Autophagy 8:754-766. http://dx.doi.org/10.4161/auto.19371
38. Filomeni G, Graziani I, De Zio D, Dini L, Centonze D, Rotilio G, Ciriolo MR. 2012. Neuroprotection of kaempferol by autophagy in models of rotenone-mediated acute toxicity: possible implications for Parkinson's disease. Neurobiol Aging 33:767-785. http://dx.doi.org/10.1016/j .neurobiolaging.2010.05.021
39. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. 1999. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 52:1214-1220. http://dx.doi.org/10.1212/WNL.52.6.1214
40. de Rijk MC, Breteler MM, Graveland GA, Ott A, Grobbee DE, van der Meche FG, Hofman A. 1995. Prevalence of Parkinson's disease in the elderly: the Rotterdam study. Neurology 45:2143-2146. http://dx.doi.org /10.1212/WNL.45.12.2143
41. Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM. 2004. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 304:596-600. http://dx.doi.org/10 .1126/science.1095569
42. Stanfel MN, Shamieh LS, Kaeberlein M, Kennedy BK. 2009. The TOR pathway comes of age. Biochim Biophys Acta 1790:1067-1074. http://dx .doi.org/10.1016/j.bbagen.2009.06.007
43. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA. 2009. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460:392-395.
44. Lee JH, Bodmer R, Bier E, Karin M. 2010. Sestrins at the crossroad between stress and aging. Aging 2:369-374.
45. Bergamini E. 2006. Autophagy: a cell repair mechanism that retards ageing and age-associated diseases and can be intensified pharmacologically. Mol Aspects Med 27:403-410. http://dx.doi.org/10.1016/j.mam.2006.08.001
46. Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J, Mouatt-Prigent A, Ruberg M, Hirsch EC, Agid Y. 1997. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 12:25-31.
47. Yu WH, Dorado B, Figueroa HY, Wang L, Planel E, Cookson MR, Clark LN, Duff KE. 2009. Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol 175:736-747. http://dx.doi.org/10.2353/ajpath.2009.080928
48. Dehay B, Bove J, Rodriguez-Muela N, Perier C, Recasens A, Boya P, Vila M. 2010. Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci 30:12535-12544. http://dx.doi.org/10.1523/JNEUROSCI.1920-10.2010
49. Janda E, Isidoro C, Carresi C, Mollace V. 2012. Defective autophagy in Parkinson's disease: role of oxidative stress. Mol Neurobiol 46:639-661. http://dx.doi.org/10.1007/s12035-012-8318-1
50. Giordano S, Lee J, Darley-Usmar VM, Zhang J. 2012. Distinct effects of rotenone, 1-methyl-4-phenylpyridinium and 6-hydroxydopamine on cellular bioenergetics and cell death. PLoS One 7:e44610. http://dx.doi.org /10.1371/journal.pone.0044610
51. Goswami P, Gupta S, Biswas J, Joshi N, Swarnkar S, Nath C, Singh S. 28 November 2014. Endoplasmic reticulum stress plays a key role in rotenone- induced apoptotic death of neurons. Mol Neurobiol http://dx.doi .org/10.1007/s12035-014-9001-5.
52. Jeong EK, Kim SJ, Oh Y, Kim H, Lee YS, Kwon BS, Park S, Park KC, Yoon KS, Kim SS, Ha J, Kang I, Choe W. 2014. p53 negatively regulates Pin1 expression under ER stress. Biochem Biophys Res Commun 454:518-523. http://dx.doi.org/10.1016/j.bbrc.2014.10.101
53. Bruning A, Rahmeh M, Friese K. 2013. Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation. Mol Oncol 7:1012-1018. http://dx.doi.org/10.1016/j.molonc.2013.07.010
54. Eid AA, Lee DY, Roman LJ, Khazim K, Gorin Y. 2013. Sestrin 2 and AMPK connect hyperglycemia to Nox4-dependent endothelial nitric oxide synthase uncoupling and matrix protein expression. Mol Cell Biol 33:3439-3460. http://dx.doi.org/10.1128/MCB.00217-13
55. Sanli T, Linher-Melville K, Tsakiridis T, Singh G. 2012. Sestrin2 modulates AMPK subunit expression and its response to ionizing radiation in breast cancer cells. PLoS One 7:e32035. http://dx.doi.org/10.1371/journal .pone.0032035
56. Canto C, Auwerx J. 2011. Calorie restriction: isAMPKa key sensor and effector? Physiology 26:214-224. http://dx.doi.org/10.1152/physiol.00010.2011
57. Merry BJ. 2002. Molecular mechanisms linking calorie restriction and longevity. Int J Biochem Cell Biol 34:1340-1354. http://dx.doi.org/10 .1016/S1357-2725(02)00038-9
58. WuY, Li X, Zhu JX, Xie W, Le W, Fan Z, Jankovic J, Pan T. 2011. Resveratrolactivated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neuro-Signals 19:163-174. http://dx.doi.org/10.1159/000328516
59. Ng CH, Guan MS, Koh C, Ouyang X, Yu F, Tan EK, O'Neill SP, Zhang X, Chung J, Lim KL. 2012. AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in Drosophila models of Parkinson's disease. J Neurosci 32:14311-14317. http://dx.doi.org/10 .1523/JNEUROSCI.0499-12.2012
60. Zimmermann A, Bachmann C, Baumgartner R. 1986. Severe liver fibrosis in argininosuccinic aciduria. Arch Pathol Lab Med 110:136-140.
61. Lee JH, Budanov AV, Park EJ, Birse R, Kim TE, Perkins GA, Ocorr K, Ellisman MH, Bodmer R, Bier E, Karin M. 2010. Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science 327:1223-1228. http://dx.doi.org/10.1126/science.1182228
62. Peng M, Yin N, Li MO. 2014. Sestrins function as guanine nucleotide dissociation inhibitors for Rag GTPases to control mTORC1 signaling. Cell 159:122-133. http://dx.doi.org/10.1016/j.cell.2014.08.038
63. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. 2003. Alpha-synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278:25009-25013. http://dx.doi.org/10.1074/jbc.M300227200
64. Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, Rockenstein E, Masliah E, Hyman BT, McLean PJ, Unni VK. 2011. Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. J Neurosci 31:14508-14520. http://dx.doi.org/10.1523/JNEUROSCI.1560-11.2011
65. Engelender S. 2012. Alpha-synuclein fate: proteasome or autophagy? Autophagy 8:418-420. http://dx.doi.org/10.4161/auto.19085
66. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, Riek R. 2011. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA108:4194-4199. http://dx.doi.org/10.1073/pnas.1100976108.
67. Dehay B, Ramirez A, Martinez-Vicente M, Perier C, Canron MH, Doudnikoff E, Vital A, Vila M, Klein C, Bezard E. 2012. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci U S A 109:9611-9616. http://dx.doi.org/10.1073/pnas.1112368109
68. Usenovic M, Tresse E, Mazzulli JR, Taylor JP, Krainc D. 2012. Deficiency of ATP13A2 leads to lysosomal dysfunction, alpha-synuclein accumulation, and neurotoxicity. J Neurosci 32:4240-4246. http://dx.doi.org /10.1523/JNEUROSCI.5575-11.2012
69. Ebrahimi-Fakhari D, McLean PJ, Unni VK. 2012. Alpha-synuclein's degradation in vivo: opening a new (cranial) window on the roles of degradation pathways in Parkinson disease. Autophagy 8:281-283. http://dx .doi.org/10.4161/auto.8.2.18938
70. Lynch-Day MA, Mao K, Wang K, Zhao M, Klionsky DJ. 2012. The role of autophagy in Parkinson's disease. Cold Spring Harbor Perspect Med 2:a009357.